Coherus Oncology (CHRS) Return on Sales: 2014-2025
Historic Return on Sales for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to 1.95%.
- Coherus Oncology's Return on Sales rose 40.00% to 1.95% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.95%, marking a year-over-year increase of 40.00%. This contributed to the annual value of 0.11% for FY2024, which is 103.00% up from last year.
- Coherus Oncology's Return on Sales amounted to 1.95% in Q3 2025, which was down 6.79% from 2.09% recorded in Q2 2025.
- In the past 5 years, Coherus Oncology's Return on Sales ranged from a high of 2.09% in Q2 2025 and a low of -1.48% during Q1 2023.
- In the last 3 years, Coherus Oncology's Return on Sales had a median value of 0.52% in 2024 and averaged 0.36%.
- Its Return on Sales has fluctuated over the past 5 years, first slumped by 116bps in 2021, then skyrocketed by 260bps in 2024.
- Coherus Oncology's Return on Sales (Quarterly) stood at -0.88% in 2021, then crashed by 50bps to -1.38% in 2022, then skyrocketed by 46bps to -0.92% in 2023, then skyrocketed by 260bps to 1.68% in 2024, then soared by 40bps to 1.95% in 2025.
- Its last three reported values are 1.95% in Q3 2025, 2.09% for Q2 2025, and 0.98% during Q1 2025.